Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs

Susan L. Longhofer From the Departments of Medical Sciences (Longhofer, Johnson, Culham, Grauer) and Pathobiological Sciences (Schultz), School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr W, Madison, WI 53706.

Search for other papers by Susan L. Longhofer in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Heidi C. Johnson From the Departments of Medical Sciences (Longhofer, Johnson, Culham, Grauer) and Pathobiological Sciences (Schultz), School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr W, Madison, WI 53706.

Search for other papers by Heidi C. Johnson in
Current site
Google Scholar
PubMed
Close
 DVM
,
Cynthia A. Culham From the Departments of Medical Sciences (Longhofer, Johnson, Culham, Grauer) and Pathobiological Sciences (Schultz), School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr W, Madison, WI 53706.

Search for other papers by Cynthia A. Culham in
Current site
Google Scholar
PubMed
Close
 DVM
,
Kevin T. Schultz From the Departments of Medical Sciences (Longhofer, Johnson, Culham, Grauer) and Pathobiological Sciences (Schultz), School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr W, Madison, WI 53706.

Search for other papers by Kevin T. Schultz in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Gregory F. Grauer From the Departments of Medical Sciences (Longhofer, Johnson, Culham, Grauer) and Pathobiological Sciences (Schultz), School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr W, Madison, WI 53706.

Search for other papers by Gregory F. Grauer in
Current site
Google Scholar
PubMed
Close
 DVM, MS

Click on author name to view affiliation information

SUMMARY

A specific thromboxane synthetase inhibitor, 3-methyl- 2 (3-pyridyl)-l-indoleoctanoic acid (CGS 12970) was administered orally to 6 healthy adult Beagles at a dosage of 30 mg/kg of body weight. Blood generation of thromboxane B2 and urinary excretion of thromboxane B2 were measured before and after administration of CGS 12970. Although 97 ± 0.4% inhibition of thromboxane B2 generation was observed within 2 hours after a single dose of CGS 12970 was administered orally, an effect on urinary excretion of thromboxane B2 was not observed. Additionally, oral administration of 30 mg/kg every 12 hours resulted in 80 ± 14% inhibition of thromboxane B2 generation but had no effect on urinary thromboxane B2 excretion.

SUMMARY

A specific thromboxane synthetase inhibitor, 3-methyl- 2 (3-pyridyl)-l-indoleoctanoic acid (CGS 12970) was administered orally to 6 healthy adult Beagles at a dosage of 30 mg/kg of body weight. Blood generation of thromboxane B2 and urinary excretion of thromboxane B2 were measured before and after administration of CGS 12970. Although 97 ± 0.4% inhibition of thromboxane B2 generation was observed within 2 hours after a single dose of CGS 12970 was administered orally, an effect on urinary excretion of thromboxane B2 was not observed. Additionally, oral administration of 30 mg/kg every 12 hours resulted in 80 ± 14% inhibition of thromboxane B2 generation but had no effect on urinary thromboxane B2 excretion.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 43 43 14
PDF Downloads 27 27 3
Advertisement